Milrinone During Living Donor Hepatectomy

This study has been completed.
Sponsor:
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT00966745
First received: August 13, 2009
Last updated: August 26, 2009
Last verified: August 2009
  Purpose

Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.


Condition Intervention
Hepatectomy
Drug: milrinone
Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique

Resource links provided by NLM:


Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • condition of surgical field [ Time Frame: intraoperative period (from the start of surgery to end of living donor hepatectomy) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively [ Time Frame: intraoperative period (from the start of surgery to end of living donor hepatectomy) ] [ Designated as safety issue: No ]

Enrollment: 38
Study Start Date: January 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: milrinone
milrinone infusion
Drug: milrinone
Placebo Comparator: placebo Drug: placebo

  Eligibility

Ages Eligible for Study:   19 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Living liver donors

Exclusion Criteria:

  • Donors with concurrent cardiac, pulmonary, and urologic disease
  • Hepatectomy performed laparoscopically
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00966745

Locations
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00966745     History of Changes
Other Study ID Numbers: mil_living_liver_donor
Study First Received: August 13, 2009
Last Updated: August 26, 2009
Health Authority: Korea: Food and Drug Administration
Korea: Ministry for Health, Welfare and Family Affairs

Keywords provided by Seoul National University Hospital:
surgical field condition

Additional relevant MeSH terms:
Milrinone
Cardiotonic Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Platelet Aggregation Inhibitors
Hematologic Agents
Vasodilator Agents
Phosphodiesterase 3 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2014